MDMA (± 3,4-methylenedioxymethamphetamine) is a psychoactive compound with unique pharmacological and therapeutic properties that differentiate it from classical psychedelics like psilocybin and LSD. While classical psychedelics primarily act as 5-HT2A receptor agonists, inducing profound perceptual and cognitive alterations, MDMA primarily stimulates the release of serotonin (5-HT), norepinephrine (NE), and dopamine (DA), while also promoting oxytocin release. This neurochemical profile contributes to its prosocial effects, including heightened emotional openness and trust, reduced fear responses, and increased receptivity to social connection, all while generally preserving cognitive clarity and perceptual stability (1). Due to these therapeutic actions, MDMA is often classified as an entactogen (promoting introspection and self-reflection) and an empathogen (enhancing empathy and compassion). More recently, the term connectogen has been proposed to better capture MDMA’s ability to foster deep, holistic connections that are both intrapersonal (entactogenic) and interpersonal (empathogenic) (79).

MDMA’s primary mechanism involves increasing the availability of 5-HT and NE, while indirectly influencing DA via monoamine transporter activity and triggering oxytocin release (79–82). These neurochemical effects contribute to mood elevation, heightened self-confidence, and greater emotional openness (1, 83). MDMA’s ability to enhance social bonding is thought to be driven by its stimulation of oxytocin release (84), which increases prosocial feelings (85), greater trust in interpersonal interactions (86), and openness to social reward and connectedness (87). Additionally, MDMA promotes a desire for social engagement, potentially by reducing sensitivity to subtle negative emotional cues in others (88). MDMA also appears to modulate fear responses by reducing activity in the amygdala, decreasing reactions to socially threatening stimuli while enhancing responses to socially rewarding signals - an effect that may influence emotional memory processing (89). Moreover, MDMA has been shown to reduce fear responses during trauma recall, likely through its effects on both the amygdala and hippocampus, facilitating memory reconsolidation (90).

MDMA’s ability to enhance global cortical connectivity and neuroplasticity is also believed to play a key role in its therapeutic effects (91). Neuroimaging studies demonstrate that MDMA increases cortical-limbic communication, integrating previously segregated brain networks while reducing rigid connectivity in associative areas - a pattern linked to greater cognitive flexibility and emotional openness (91). Additionally, MDMA reduces activity in the Default Mode Network (DMN), potentially loosening rigid self-referential thinking patterns (92). Given that PN is characterized by inflexible and defensive cognitive processes, MDMA’s capacity to soften entrenched self-concepts may have significant therapeutic implications. MDMA’s influence on the salience network also facilitates a shift toward positive emotional experiences, reinforcing affective learning and emotional regulation (93, 94). This suggests a therapeutic potential for PN, where hypersensitivity to social evaluation contributes to maladaptive interpersonal dynamics. By reducing excessive salience network activity, MDMA may help individuals with narcissistic traits to recalibrate their emotional responses and engage more adaptively in social interactions.

Neuroimaging studies indicate that individuals with high narcissistic traits exhibit reduced grey matter volume in the anterior cingulate cortex (ACC), medial prefrontal cortex (mPFC), and dorsolateral prefrontal cortex (dPFC) - regions critical for self-awareness, emotion regulation, and social cognition (58, 95). Despite these structural differences, individuals with PN display heightened anterior insula (AI) and dorsal ACC (dACC) activity in response to social exclusion, indicating increased rejection sensitivity despite an outward appearance of emotional detachment (96). By enhancing ACC function and promoting cognitive flexibility, emotion regulation, and fear extinction via 5-HT2A receptor activation (97), MDMA may help reduce defensive rigidity and social threat hypersensitivity - core features of PN that contribute to its paradoxical combination of emotional detachment and heightened sensitivity to threats against self-image or social status (98). Additionally, MDMA’s modulation of the amygdala and salience network may attenuate exaggerated threat responses to social evaluation, facilitating more adaptive interpersonal processing (98). By reducing defensive rigidity and enhancing emotional openness, MDMA may help individuals with PN engage more flexibly in social interactions.

MDMA’s ability to modulate neurotransmitters, enhance neuroplasticity, reorganize brain networks, and influence emotional processing ultimately leads to the activation of core emotional circuits and unconscious mechanisms. Clinical studies consistently link psychedelic experiences to increased access to emotions, memories, and perceptions typically avoided or outside conscious awareness (99, 100). How do these neurobiological changes translate into the profound therapeutic shifts observed in PAT? The REBUS (Relaxed Beliefs Under Psychedelics) model, proposed by Carhart-Harris and Friston (101), offers a functional framework for understanding brain dynamics under psychedelics. It suggests that psychedelics “relax” high-level cortical cognitive structures, or “priors” - deep-seated beliefs and assumptions that shape how individuals perceive and interpret the world. These priors often suppress new information to maintain a stable worldview, even when this results in rigid or pathological thinking patterns that contribute to mental illness. Under the influence of psychedelics, the precision of these priors is reduced, allowing bottom-up subcortical sensory information, along with dissociated memories, emotions, and thoughts, to surface. This process creates a therapeutic window during PAT in which entrenched pathological beliefs can be revised, promoting psychological flexibility. This window represents the opening of a critical learning period, that promotes plasticity in thought, emotion, behavior, and interpersonal relationships that lasts for approximately two weeks after an MDMA session (87).

MDMA creates a state of heightened openness and emotional receptivity that extends beyond the acute drug experience, offering a critical window for therapeutic intervention. MDMA’s softening of rigid self-protective mechanisms reduces interpersonal defensiveness, and increases sensitivity to emotional and relational dynamics, allowing for deeper engagement in the therapeutic process (88, 100, 102). These effects are particularly relevant for narcissistic patients whose defense mechanisms often preclude emotional insight and connection. The two-weeks following MDMA administration is associated with increased neuroplasticity and psychological flexibility making it an important time for integration. Given this extended window of time, the structure and approach of psychotherapy during MDMA-AT become central considerations.

The role of psychotherapy in psychedelic treatment remains a subject of debate (103). Key discussions focus on whether psychotherapy should accompany psychedelic use and, if so, the optimal amount and most efficacious approach. Some argue that psychedelics could serve as standalone treatments, with psychological support primarily serving a safety function (104). Others highlight the scalability and cost-effectiveness of PAT, advocating for research into shorter, more affordable treatment schedules (105).

Conversely, proponents of a synergistic approach contend that psychedelics enhance therapeutic outcomes when combined with psychotherapy (106–109). Debate continues over which therapeutic modalities best complement psychedelic treatment (110–112), with various adapted and ad hoc models being evaluated in clinical research presently (106). Further research is needed to identify the most efficacious therapeutic modalities that synergize with psychedelics to optimize clinical outcomes (103). Clarifying which therapeutic modalities best complement psychedelic treatment remains a key priority for future research (103).

Amid these ongoing debates, the absence of clinical trials exploring psychoanalytic approaches to PAT is particularly notable. Despite substantial evidence supporting the efficacy of psychoanalytic modalities, research has largely overlooked their integration with psychedelic therapy as well as their compatibility. Importantly, there appears to be growing support among psychoanalysts as well as psychiatrists for psychedelic-assisted therapies for their patients (113, 114). Unlike the more manualized treatments, psychoanalytic therapy is inherently open-ended, following and supporting a patient’s largely self-directed process. This flexibility makes it particularly compatible with psychedelics, whose effects are often unpredictable and require therapists to adapt to patients’ evolving processes (103). Moreover, although they operate on different timescales, psychoanalytic therapy and psychedelics share a remarkable therapeutic convergence. Both approaches are believed to activate the brain’s core emotional systems and unconscious processes to result in psychological change.

Contemporary psychoanalytic theory posits that psychological disorders arise from failures to meet innate emotional needs (115). ³ Neurobiological findings align with key psychoanalytic concepts, particularly regarding instinctive needs, unconscious processing, and the centrality of affect in mental life (115, 116). These findings suggest that feelings originate in subcortical structures and serve as expressions of basic unmet emotional needs and motivations. Unlike physiological symptoms, psychological ones carry meaning and intention, reflecting the patient’s struggle to satisfy these needs (e.g., panic arises from fear of losing an attachment, while rage occurs when the satisfaction of one’s needs is frustrated). Deeply rooted in early life experiences, coping behaviors become unconscious automatic responses or “automatized predictions” (115) over time. Developed to fulfill unmet needs and based on learned experiences from the past, these unconscious patterns of behavior are not consciously remembered but are automatically re-enacted – that is, replayed in current relationships or situations as an attempt to gain mastery over or integrate unresolved psychological conflicts (117, 118). In short, both psychoanalytic and psychedelic therapy facilitate access to the unconscious to revise unconscious processes (i.e., “automatized predictions” per psychoanalytic theory and “priors” per the REBUS model), adapt emotional regulation, and rework patterns of relating to oneself and others, ultimately driving personality transformation.

Psychoanalytic treatment helps patients recognize and work through unconscious conflicts that shape their emotions and behaviors. By bringing unconscious coping mechanisms into awareness, it enables individuals to break maladaptive patterns, address unmet needs, and develop healthier ways of regulating emotions. Psychoanalytic therapy has demonstrated efficacy comparable to other evidence-based treatments, such as cognitive-behavioral therapy (CBT), while remaining distinct in its emphasis on early development and unconscious processes (119). Its effect sizes range from 0.78 to 1.46, comparable to or even exceeding those of other evidence-based treatments (120, 121). Comparison studies of depression treatments indicate that psychoanalytic psychotherapies emphasizing interpersonal and developmental experiences lead to both short- and long-term improvement, with a developmental focus predicting longer recovery and better functioning over 24 months than other therapies (122). Research indicates that combining psychoanalytic techniques with cognitive therapy enhances treatment outcomes, whereas cognitive techniques alone demonstrate limited association with long-term improvements (123).

Its distinctive focus on increasing awareness of unconscious feelings, beliefs, and reflexive coping patterns - rather than just symptom relief - may explain why psychoanalytic therapy is particularly efficacious for facilitating lasting transformation compared to cognitive-behavioral approaches (124). Research suggests that the benefits of psychoanalytic therapy not only endure, but its effect size may actually increase over time, reaching up to 1.51 at long-term follow-up (120, 121). This phenomenon, known as the “sleeper effect,” implies that psychoanalytic therapy initiates ongoing processes of change that continue to evolve even after therapy has ended (121).

With the unique characteristics of psychoanalytic therapy empirically distinguished from other treatment methods (125), neuropsychoanalysis pioneer Solms (115) has identified key psychoanalytic techniques that align with neuroscientific findings and are associated with optimal treatment outcomes. These techniques are thought to engage the brain’s deeper emotion-driven systems, facilitating long-term psychological change. Notably, while these same techniques are fundamental to psychoanalytic therapy, research suggests they also contribute to effective outcomes across various therapeutic orientations, including CBT, even when their influence is not explicitly recognized (121):

With its attention on the here-and-now, psychoanalytic therapy is uniquely suited to PAT. Zamaria et al. (103) describe PAT as inherently relational, which is in keeping with the contemporary ethos of psychoanalytic therapy, where the importance of the therapist-patient dynamic helps facilitate change. Attending to the therapy relationship often reveals unconscious conflicts, particularly through transference, which involves patients projecting past emotions and expectations onto the therapist. These projections are largely shaped by early childhood attachment experiences and interpersonal patterns, reflecting deeply ingrained relational templates (14, 115, 126). Countertransference, in turn, refers to the therapist’s emotional reactions, often influenced by their own unresolved conflicts. Once made conscious, these unconscious patterns offer key insights into relational dynamics and can serve as powerful tools for fostering self-understanding and transformation.

With its focus on uncovering entrenched intra- and interpersonal dynamics, psychoanalytic therapy offers a structured framework for treating personality disorders, particularly PN, where rigid behavioral defenses often impede progress. While psychoanalytic therapy facilitates personality restructuring, MDMA-assisted therapy enhances emotional openness and access to unconscious material. However, their combined potential remains unexplored. By integrating their complementary mechanisms, we propose a novel framework to optimize therapeutic outcomes for PN.

Core indicators of change in PN identified by Ronningstam and Weinberg (78) will be utilized to measure treatment efficacy. Their research importantly demonstrates that patients with PN are capable of change (78) and that meaningful therapeutic progress is linked to improvements in reflective functioning and self-awareness, emotion regulation and tolerance, and a strengthened sense of agency (78). They also emphasize that a strong therapeutic alliance can foster self-reflection and emotion regulation in patients with PN, while increasing awareness of their internal experiences and interpersonal impact. In turn, these effects may reduce defensiveness and enhance empathy and self-compassion (128), further supporting therapeutic change.

Changes in personality pathology and functioning are best understood as a multifactorial, integrative process, in which various factors, individual characteristics, and contextual influences can either facilitate or hinder a patient’s capacity for change. Ronningstam and Weinberg (78) found that therapeutic interventions promoting self-reflection, agency, and openness to new experiences were essential for patients with PN, from the first therapeutic session onward. By operationalizing these indicators as treatment outcomes, our study introduces MDMA as a novel factor that may enhance patient openness and facilitate engagement with the therapeutic process. If MDMA-AT promotes greater receptivity to self-examination and emotional processing, it could play a significant role in overcoming the psychological barriers that often impede change in PN and support its potential as an intervention for narcissistic pathology.

Reflective functioning, or mentalization, is the ability to understand one’s own and others’ thoughts and feelings (129). It is essential for self-regulation and interpersonal functioning, enabling individuals to process emotions, adjust maladaptive patterns, and build healthier relationships. Deficits in mentalization are linked to personality disorders, including PN, where individuals often engage in intellectualized, detached rumination rather than genuine reflection (129, 130). Enhanced reflective capacity is a key mechanism of change in personality disorder treatment (131). Ronningstam and Weinberg (78) highlight reflective functioning as central to change in narcissistic individuals, facilitating a shift from blame and avoidance to responsibility and collaboration. Mentalization-based therapy (MBT) has been adapted to address these deficits in PN, with theoretical and clinical support suggesting it promotes a transition from a rigid, self-focused “me-mode” to a more relational “we-mode,” leading to greater self-reflection, emotional awareness, and perspective-taking (132). Improvement in reflective ability in PN not only signals change but also contributes to better emotion regulation, increased self-agency, and stronger therapeutic engagement (78).

In the 1970s, MDMA was used in psychotherapy to enhance self-awareness (79). Among recreational MDMA users, MDMA use has been linked to increased self-compassion and reduced self-criticism post-use (133). Research shows MDMA increases authenticity, self-acceptance, and introspection, all supporting reflective functioning (79). MDMA has been shown to improve psychological flexibility, reduce fear of negative evaluation, and enhance self-reflection (89, 134–136). Additionally, MDMA has demonstrated it enhances metacognitive capacity, promoting self-other differentiation and deeper emotional processing, both of which are crucial in working with narcissistic pathology (137). Its prosocial effects foster emotional openness and increased social cognition (138, 139). These findings suggest MDMA could help narcissistic patients engage more deeply in self-reflective processes necessary for therapeutic change.

Blay et al. (140) provide evidence that impaired self-mentalization drives emotion dysregulation in narcissistic individuals, making both key treatment targets. MDMA facilitates introspection and emotional integration (137, 138). While research on MDMA’s effects on mentalization in structured therapy is limited, its observed impact on self-reflection and emotional processing suggests potential for further study. Given that mentalization deficits contribute to personality pathology (141), investigation is warranted to assess MDMA’s role in enhancing reflective functioning in PN.

Developing emotional tolerance and regulation is essential for therapeutic progress in narcissistic individuals (78, 128). Patients with PN struggle to access, recognize, and articulate their emotional experiences (60). Emotion regulation involves integrating painful experiences, mourning losses, and accepting personal limitations. Psychoanalytic theory has long emphasized grief as central to emotional development and mental health (142). Bowlby (143) identified mourning as crucial for adaptation, while Kohut (144) linked narcissistic injuries to unmet childhood needs, necessitating the grieving of idealized self and other representations. Narcissistic defenses - grandiosity, idealization, and devaluation - serve to protect against overwhelming loss, past deprivations, and the realities of life (129, 145).

Anger and aggression are closely linked to narcissistic pathology, and can manifest as self-directed criticism and negativity as well as outward hostility through devaluation, criticism, and attacking behaviors toward others (78, 145, 146). These individuals struggle to acknowledge and process distressing emotions including shame, humiliation, rage, and envy (128, 132, 146). At a neurological level, narcissists experience social rejection as deeply distressing, yet they may not outwardly express it, potentially leading to reactive aggression and relational instability (96). Processing painful emotions has been shown to help narcissists reduce maladaptive behaviors while increasing resilience, self-compassion, and empathy (147). Kramer et al. (128) identified emotion processing - particularly the interplay of shame and self-compassion - as facilitating change in the treatment of narcissistic patients with comorbid depression. Improved capacity to regulate one’s emotions may support the narcissist’s development of a more cohesive self-experience (78).

Alexithymia, or difficulty identifying, describing, and expressing one’s own emotions, is strongly associated with PN, where deficits in emotion identification and metacognition contribute to maladaptive coping and emotional dysregulation (74, 140, 148). Additionally, deficits in emotional recognition - the ability to perceive and interpret emotions in others - have been observed in narcissistic patients, suggesting that impaired affective processing underlies interpersonal insensitivity (149). A mentalization-based treatment approach has been explored as a potential intervention for narcissistic individuals, with theoretical support suggesting it may enhance emotional awareness and reflective capacity to reduce maladaptive coping strategies, though direct empirical validation remains limited (74).

MDMA has shown potential in enhancing emotion regulation and tolerance. It reduces the brain’s fear-avoidance response, enabling individuals to access and reprocess overwhelming emotions that might otherwise be too distressing for narcissistic patients to confront (140). When recalling autobiographical memories, MDMA increases emotional intensity and positive affect, suggesting it could facilitate emotional processing in PN (139). Additionally, MDMA enhances positive emotional experiences while blunting negative ones, potentially reducing defensive responses and increasing emotional flexibility (79, 150). Moreover, it promotes openness and trust, helping individuals engage with difficult emotions in therapy (151).

MDMA also facilitates emotional disclosure and increases comfort in discussing personal feelings (136, 137), which could be particularly important for narcissists with alexithymia, who struggle to identify and express their emotions. It enhances affective empathy for positive emotions while impairing recognition of negative emotions, such as sadness or fear, which could potentially help narcissistic individuals tolerate and engage with emotions they would otherwise suppress (152). MDMA’s ability to reduce reactivity to negative emotional stimuli could mitigate avoidance and defensiveness in therapeutic settings, both reinforcing its relevance as an intervention targeting emotional tolerance and regulation and suggesting that MDMA-AT could help narcissistic individuals to engage with difficult emotions in therapy (151, 153).

Rooted in feelings of inferiority and powerlessness, individuals with PN tend to exhibit a strong drive for control, particularly in their interpersonal relationships (130, 146). To protect their self-image and ward off underlying insecurities, narcissistic patients frequently engage in power struggles, assuming a position of dominance and superiority and resorting to the externalization of blame (145, 154). In spite of this, many have difficulties setting goals beyond self-aggrandizement and struggle to accept the reality that achieving ambitions requires commitment, effort, and the ability to tolerate frustration (129). Brown et al. (155) found that perceived agency differentiates grandiose and vulnerable narcissism, with self-esteem mediating their relationship. While individuals exhibiting more narcissistic grandiosity tend to maintain self-esteem through agentic behaviors like self-promotion, those in more vulnerable states experience lower self-agency, contributing to diminished self-worth. Strengthening self-agency may help counteract feelings of impotence rooted in past experiences of powerlessness and helplessness.

Their need for control can manifest as a resistance to change, sometimes impeding therapeutic progress (78, 130, 145). Narcissistic patients benefit from a balance of expressive interventions that offer interpretive insights when they are receptive and supportive strategies during periods of heightened vulnerability or narcissistic injury (71). Framing interpretations as hypotheses encourages collaboration and engagement, supporting self-agency. In psychoanalytic treatment, allowing the patient to take the lead reinforces their ownership of the therapeutic process (71). Flexibility in therapy empowers the patient and ensures the therapist remains responsive to their unique needs. By facilitating open-ended dialogue, the therapist can adapt their approach to the patient’s evolving needs and readiness for support (156). Given that narcissistic functioning very frequently interferes with their ability to learn from life experiences (98), therapy provides a unique opportunity to process these in a new way, promoting insight and adaptive change (78). Therapists must balance strengthening autonomy with fostering interdependence, guiding patients toward relational reciprocity.

MDMA has demonstrated potential in enhancing self-agency through greater self-acceptance, psychological openness, and emotional awareness. Research suggests that MDMA reduces social defensiveness and increases authenticity, enabling individuals to take greater ownership of their emotions and actions (79). Kuypers (157) and Hysek et al. (81) found that MDMA enhances self-compassion and empathy and facilitates deeper self-reflection and interpersonal engagement, which may promote self-efficacy in these patients. Recent studies have shown that MDMA-AT improves self-experience in patients with PTSD, including their self-compassion and emotional regulation (6). These findings highlight the value of evaluating MDMA’s capacity to foster self-agency in narcissistic pathology.

The therapeutic alliance is a well-established predictor of positive treatment outcomes across a range of psychotherapeutic modalities (158–160), including psychoanalytic psychotherapy (161) and the treatment of personality disorders such as PN (162, 163). Beyond facilitating change, the alliance itself often becomes a central focus of treatment for individuals with personality disorders, providing a relational context for addressing core interpersonal difficulties (164).

For patients with PN, forming and maintaining a strong alliance is often hindered by dismissive attachment styles, distrust toward the therapist, and excessive self-reliance (59, 129). These patients struggle with interpersonal closeness, perceiving dependency as a threat to their autonomy. As a result, they frequently oscillate between idealization and devaluation of the therapist, making the therapeutic bond unstable. These relational patterns reflect the broader interpersonal difficulties characteristic of PN. Empathic listening and validation of the patient’s suffering help regulate affect and strengthen the alliance (165), while warmth and understanding engender trust and receptivity (78). Once trust is established, narcissistic patients become more open to therapeutic challenges and alternative perspectives. Thus, the therapeutic relationship serves both as a mechanism of change - allowing patients to process emotional experiences in real time - and as a treatment goal, resulting in more adaptive relational patterns (164, 165).

A key factor in maintaining the alliance is the ability to openly address relational dynamics within the therapy. Weinberg (70) emphasizes that managing ruptures and enactments through gentle confrontation is essential for maintaining engagement in therapy, with the therapist’s availability serving as a stabilizing factor. By processing these relational patterns, within the therapeutic relationship, patients can experience corrective emotional experiences that help shift maladaptive interaction styles toward healthier, more reciprocal ones (166–168). Addressing early attachment disruptions in this relational context fosters a more cohesive self-concept, strengthens self-agency and improves interpersonal functioning (167).

Studies indicate that the therapist-patient relationship is one of the strongest predictors of treatment success across psychotherapeutic approaches, including PAT (166, 169–171). Enhancing the therapeutic alliance has significant clinical implications, particularly in modalities emphasizing relational dynamics. MDMA’s unique pharmacological properties may facilitate alliance formation by increasing compassion, empathy, and emotional engagement, which contribute to deeper therapeutic work (6, 158). Research suggests that MDMA fosters trust, openness, and social bonding, essential for a strong therapeutic alliance (79). Additionally, its prosocial effects - such as increased sociability and decreased social sensitivity - have been linked to improved therapeutic engagement (81, 88), making patients less guarded and more willing to explore painful emotional material. MDMA-AT has also been shown to improve emotional regulation and strengthen self-experience, particularly in individuals with impaired self-coherence, such as those with PN (137).

Clinical trials indicate that MDMA-AT enhances key factors necessary for a robust therapeutic alliance, including self-compassion, emotional awareness, and relational capacities (158). By facilitating authentic emotional disclosure and self-reflection, MDMA enables patients to engage more deeply in therapy (136). For patients with PN, who are prone to interpersonal defensiveness and hypersensitivity to social rejection, MDMA’s ability to reduce perception of social threat may be particularly beneficial (89). By decreasing reactivity to perceived criticism and enhancing emotional empathy (152), MDMA may help narcissistic patients tolerate vulnerability and interpersonal closeness without triggering defensiveness. Additionally, by dampening reactivity to negative emotional stimuli, MDMA may support more constructive engagement with distressing relational patterns (153). Integrating MDMA-AT with psychoanalytic principles may further establish the therapeutic relationship as a corrective emotional experience, fostering meaningful psychological change in individuals with PN (170, 171).